newsfilter
← Latest News
Business Wire·

AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTX
  • Global Phase 2 study of oral epetraborole for polycythemia vera received regulatory clearance in all planned jurisdictions including the U.S., Australia, & India; enrollment is expected to begin by year-end 2026.
  • Enrollment is ongoing for a Phase 2 investigator-initiated trial of epetraborole targeting M. abscessus lung disease, with top-line results anticipated in late 2027.
  • Startup activities are advancing for a Phase 2 proof-of-concept study of AN2-502998 in chronic Chagas disease.
  • AN2-504661 was selected as the oral development candidate for hypophosphatasia (HPP), with a Phase 1 study planned for the second half of 2027.
  • The Gates Foundation awarded extended third-party funding to support AN2 Therapeutics' tuberculosis research collaboration with GSK.
  • Cameron Trenor, M.D., was appointed as Chief Medical Officer in August 2026.
  • Third quarter 2026 Research & Development expenses totaled $5.7 million, down from $7.0 million in the same period of 2025.
  • General & Administrative expenses for the third quarter of 2026 were $2.9 million, compared to $3.0 million in 2025.
  • Net loss for the third quarter ended September 30, 2026, was $8.0 million, representing a decrease from $9.4 million in the prior year period.
  • The company reported cash, cash equivalents, & investments of $80.2 million as of September 30, 2026, projecting operations to be sustained into 2029.